News Briefing channel feed

Con­nect shrinks time­line for atopic der­mati­tis da­ta; Bi­cy­cle's wheels keep turn­ing with Genen­tech

3 years ago

Trio of biotechs raise funds to make en­zymes and de­vel­op drugs for IBS and oth­er au­toim­mune dis­eases

3 years ago

Astel­las finds an­oth­er col­lab­o­ra­tor in small UK start­up; Two Japan­ese biotechs align on gene ther­a­pies

3 years ago

9 Me­ters Bio­phar­ma and Cara Ther­a­peu­tics tout mid-stage da­ta for gas­troin­testi­nal, pru­ri­tus stud­ies

3 years ago

Gray­bug seeks al­ter­na­tive op­tions for eye drugs; RA-backed epilep­sy out­fit se­cures $40M Se­ries C

3 years ago

Mi­to­chon­dria biotech re­ceives Morn­ing­side buy­out of­fer af­ter PhII fail; On­col­o­gy mi­cro­cap with­draws IPO plans

3 years ago

Ever­est Med­i­cines reach­es its first peak in Chi­na with Trodelvy nod; Cy­cle­ri­on touts da­ta in small study

3 years ago

Im­mat­ics and Ed­i­tas part­ner on gene edit­ing and T cells; Eye­n­ovia founder to step down from CEO po­si­tion

3 years ago

EU re­port­ed­ly eye­ing vac­cines deal for mon­key­pox out­break; Nas­daq tells Mereo to get stock price up or face delist­ing

4 years ago

Biotech SPAC takes IPO goal down a notch; Africa’s top health agency warns against mon­key­pox vac­cine hoard­ing

4 years ago

Chica­go-area biotech sends 2nd drug to In­di­a's reg­u­la­tors; Pen­ny stock play­er spins out PhI­II can­cer can­di­date in­to new com­pa­ny

4 years ago

FDA ac­cepts pri­or­i­ty re­view of CSL-uniQure he­mo­phil­ia B gene ther­a­py; Fo­s­un Phar­ma nets an­oth­er deal

4 years ago

A cell ther­a­py biotech finds a de­liv­ery part­ner; FDA re­moves clin­i­cal hold on Ocu­gen's Covid can­di­date

4 years ago

Lon­don biotech com­pletes $2.5M mi­cro IPO; AGTC touts ear­ly gene ther­a­py da­ta — but in­vestors keep their dis­tance

4 years ago

My­ovan­t's Myfem­bree sN­DA gets new PDU­FA af­ter CRL spec­u­la­tion; In­xMed bags more funds for piv­otal stud­ies

4 years ago

BerGen­Bio nar­rows R&D to fo­cus on NSCLC and Covid-19; Oral SERDs see an­oth­er set­back as G1 drops pro­gram

4 years ago

RA-backed Pep­Gen sets terms for up­com­ing IPO; Sanofi com­mences dos­ing of De­nali can­di­date in ALS

4 years ago

Mar­tin Shkre­li fails to over­turn life­time phar­ma ban — again; Dai­ichi Sankyo and Vi­Gen­eron re-up eye dis­ease deal

4 years ago

Alzheimer's biotech Alzheon nets $50M Se­ries D; Evelo puts PhI atopic der­mati­tis pro­gram on hold

4 years ago

Mer­ck ex­tends pact with NK cell spe­cial­ists at Arti­va; Re­gen­eron-al­lied biotech pen­cils in $15M IPO

4 years ago

SEC to pro­pose new rules to rein in SPACs — re­port; mR­NA start­up lands $27M launch round

4 years ago

Antares Phar­ma wins FDA OK for oral testos­terone treat­ment; Eye-fo­cused biotech re­ports PhI­II da­ta for pupil di­la­tion drug

4 years ago

Af­ter CRL, CorMedix says new fil­ing has been ac­cept­ed by FDA; Spine Bio­Phar­ma nets a mod­est Se­ries B

4 years ago

EQRx links arms with In­sil­i­co on that two-let­ter buzz­word (AI); De­spite miss in pre­vi­ous­ly treat­ed pa­tients, Ri­bom­ic push­ing eye drug for­ward

4 years ago
First page Previous page 22232425262728 Next page Last page
A service from the Financial Times